Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX
-
Published:2022-07-25
Issue:
Volume:12
Page:
-
ISSN:2234-943X
-
Container-title:Frontiers in Oncology
-
language:
-
Short-container-title:Front. Oncol.
Author:
Zhang Xi,Chen Qing-hong,Yang Ying,Lin Jing-xin,Li Yan-chun,Zhong Tian-yu,Chen Jie,Wu Si-qi,Chen Xiao-hu,Zhou Rui-si,Lin Jia-man,Wang Dong-qing,He Qiu-xing,You Yan-ting,Zhou Xing-hong,Zuo Qiang,Liu Yan-yan,Cheng Jing-ru,Wu Yi-fen,Zhao Xiao-shan
Abstract
BackgroundHigh serum uric acid (SUA) levels increase the risk of overall cancer morbidity and mortality, particularly for digestive malignancies. Nevertheless, the correlation between SUA level and clinical outcomes of the postoperative patients with colorectal cancer (CRC) treated by chemotherapy is unclear. This study aimed at exploring the relationship between baseline SUA level and progression-free survival (PFS), disease control rate (DCR), and safety in postoperative CRC patients receiving chemotherapy.Patients and MethodsWe conducted a retrospective study to evaluate the relationship between baseline SUA level and PFS, DCR, and incidence of serious adverse events of 736 postoperative CRC patients treated with FOLFOX, FOLFIRI or XELOX at our center.ResultsData from our center suggested that high baseline SUA level is linked to poor PFS in non-metastatic CRC patients using FOLFOX (HR=2.59, 95%CI: 1.29-11.31, p=0.018) and in male patients using FOLFIRI (HR=3.77, 95%CI: 1.57-39.49, p=0.012). In patients treated by FOLFIRI, a high SUA is also linked to a low DCR (p=0.035). In patients using FOLFOX, high baseline SUA level is also linked to a high incidence of neutropenia (p=0.0037). For patients using XELOX, there is no significant correlation between SUA level and PFS, effectiveness, or safety.ConclusionsThese findings imply that a high SUA level is a promising biomarker associated with poor PFS, DCR and safety of postoperative CRC patients when treated with FOLFOX or FOLFIRI.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Guangdong Province
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology